MATTHEW JAMES BAKER
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- NAPLES, FL
- NPI
- 1154372167
- Received
- $1,434,329 in 2,277 records, 2019 to 2025 ($1,428,854 general, $5,475 research)
- As principal investigator
- $3,996,703 of research payments to others in 311 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 346 | $288,318 |
| 2024 | General payment | 368 | $215,911 |
| 2023 | General payment | 328 | $178,734 |
| 2023 | Research payment | 2 | $3,337 |
| 2022 | General payment | 307 | $196,817 |
| 2021 | General payment | 273 | $144,494 |
| 2020 | General payment | 214 | $146,963 |
| 2019 | General payment | 423 | $257,613 |
| 2019 | Research payment | 16 | $2,137 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 410 | $1,126,473 |
| Consulting Fee | 51 | $125,507 |
| Travel and Lodging | 393 | $118,710 |
| Food and Beverage | 1,370 | $54,714 |
| Research payment | 18 | $5,475 |
| Honoraria | 2 | $2,150 |
| Education | 32 | $1,258 |
| Gift | 1 | $40 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | E.R. Squibb & Sons, L.L.C. | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-12-23 | E.R. Squibb & Sons, L.L.C. | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-12-23 | Mallinckrodt Hospital Products Inc. | $46 | Travel and Lodging | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-12-23 | ARGENX US, INC. | $19 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-12-19 | Amgen Inc. | $28 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-12-19 | Vanda Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-12-18 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-12-17 | Biogen, Inc. | $4,795 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYSABRI Biological, Neurology | 2025 | |
| 2025-12-17 | Biogen, Inc. | $140 | Travel and Lodging | Cash or cash equivalent | TYSABRI Biological, Neurology | 2025 | |
| 2025-12-17 | Biogen, Inc. | $33 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-12-15 | EMD Serono, Inc. | $7,935 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-12-15 | EMD Serono, Inc. | $5,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-12-15 | Mallinckrodt Hospital Products Inc. | $31 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-12-15 | Biogen, Inc. | $23 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-12-11 | GENZYME CORPORATION | $35 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-10 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-12-04 | EMD Serono, Inc. | $5,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-12-04 | Mallinckrodt Hospital Products Inc. | $3,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-12-04 | EMD Serono, Inc. | $2,415 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-12-04 | Alexion Pharmaceuticals, Inc. | $1,770 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-12-03 | E.R. Squibb & Sons, L.L.C. | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-12-03 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-12-02 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-12-02 | TG Therapeutics, Inc. | $126 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-12-02 | E.R. Squibb & Sons, L.L.C. | $71 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-12-02 | TG Therapeutics, Inc. | $39 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-25 | Biogen, Inc. | $15 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-11-24 | E.R. Squibb & Sons, L.L.C. | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-11-24 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-11-20 | Alexion Pharmaceuticals, Inc. | $4,720 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | E.R. Squibb & Sons, L.L.C. | $1,009 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-11-20 | E.R. Squibb & Sons, L.L.C. | $121 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-11-20 | EMD Serono, Inc. | $29 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | EMD Serono, Inc. | $946 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-19 | EMD Serono, Inc. | $651 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-19 | EMD Serono, Inc. | $276 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-19 | EMD Serono, Inc. | $123 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-18 | EMD Serono, Inc. | $757 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-18 | EMD Serono, Inc. | $749 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-18 | EMD Serono, Inc. | $706 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-18 | EMD Serono, Inc. | $473 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-18 | EMD Serono, Inc. | $121 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-18 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-11-17 | Biogen, Inc. | $23 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-11-17 | Grifols USA, LLC | $22 | Food and Beverage | In-kind items and services | Gamunex-C Biological, Immunology and Neurology | 2025 | |
| 2025-11-14 | TG Therapeutics, Inc. | $5,062 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-14 | TG Therapeutics, Inc. | $842 | Travel and Lodging | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-14 | TG Therapeutics, Inc. | $116 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-14 | TG Therapeutics, Inc. | $16 | Food and Beverage | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-13 | Alexion Pharmaceuticals, Inc. | $248 | Travel and Lodging | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-11-13 | Alexion Pharmaceuticals, Inc. | $189 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-13 | Alexion Pharmaceuticals, Inc. | $134 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-13 | Alexion Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-11-12 | ABBVIE INC. | $3,675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-11-12 | TG Therapeutics, Inc. | $465 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-12 | Biogen, Inc. | $132 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-11-11 | E.R. Squibb & Sons, L.L.C. | $122 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-11-06 | Biogen, Inc. | $5,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-11-06 | Biogen, Inc. | $193 | Travel and Lodging | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-11-06 | Biogen, Inc. | $121 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-11-04 | E.R. Squibb & Sons, L.L.C. | $179 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-11-04 | Mallinckrodt Hospital Products Inc. | $137 | Travel and Lodging | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-11-04 | Mallinckrodt Hospital Products Inc. | $32 | Travel and Lodging | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-11-04 | UCB, Inc. | $31 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-11-04 | Mallinckrodt Hospital Products Inc. | $29 | Travel and Lodging | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-11-04 | E.R. Squibb & Sons, L.L.C. | $28 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-11-04 | Mallinckrodt Hospital Products Inc. | $27 | Food and Beverage | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-11-04 | EMD Serono, Inc. | $19 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-03 | Medtronic, Inc. | $18 | Food and Beverage | In-kind items and services | PERCEPT PC BRAINSENSE Device, Deep Brain Neurostimulation | 2025 | |
| 2025-11-03 | UCB, Inc. | $1 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-10-29 | ABBVIE INC. | $148 | Travel and Lodging | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-10-29 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-10-28 | Amgen Inc. | $97 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-10-27 | ARGENX US, INC. | $137 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-10-24 | EMD Serono, Inc. | $48 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-10-24 | UCB, Inc. | $43 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-10-24 | EMD Serono, Inc. | $30 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-10-24 | EMD Serono, Inc. | $4 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-10-21 | Eisai Inc. | $20 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-10-20 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-10-16 | Mallinckrodt Hospital Products Inc. | $6,540 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-10-16 | Novartis Pharmaceuticals Corporation | $33 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-10-16 | Biogen, Inc. | $18 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-10-15 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-14 | E.R. Squibb & Sons, L.L.C. | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-10-14 | Mallinckrodt Hospital Products Inc. | $746 | Travel and Lodging | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-10-13 | Amgen Inc. | $23 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-10-13 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-10-09 | Alexion Pharmaceuticals, Inc. | $4,720 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-09 | GENZYME CORPORATION | $32 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-06 | EMD Serono, Inc. | $7,935 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-10-06 | Biogen, Inc. | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-10-06 | EMD Serono, Inc. | $3,795 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-10-06 | Biogen, Inc. | $125 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-10-06 | EMD Serono, Inc. | $19 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-06 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-10-04 | Genentech USA, Inc. | $6,525 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-04 | Genentech USA, Inc. | $659 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-04 | Genentech USA, Inc. | $371 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-04 | Genentech USA, Inc. | $166 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-10-04 | Genentech USA, Inc. | $93 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-04 | Genentech USA, Inc. | $70 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-04 | Genentech USA, Inc. | $66 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-04 | Genentech USA, Inc. | $16 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-03 | Alexion Pharmaceuticals, Inc. | $145 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-10-03 | Alexion Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-02 | ABBVIE INC. | $1,181 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-10-02 | E.R. Squibb & Sons, L.L.C. | $192 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-10-02 | E.R. Squibb & Sons, L.L.C. | $121 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-10-01 | Amneal Pharmaceuticals LLC | $17 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-09-30 | ARGENX US, INC. | $112 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-09-30 | Eisai Inc. | $29 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-09-30 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-09-30 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-09-28 | TG Therapeutics, Inc. | $30 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-26 | Ares Trading SA | $3,127 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-25 | Amgen Inc. | $83 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-24 | GENZYME CORPORATION | $188 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-23 | TG Therapeutics, Inc. | $81 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-23 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-09-18 | UCB, Inc. | $37 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-09-16 | EMD Serono, Inc. | $930 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-16 | EMD Serono, Inc. | $723 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-16 | EMD Serono, Inc. | $455 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-16 | EMD Serono, Inc. | $387 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-16 | EMD Serono, Inc. | $184 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-16 | EMD Serono, Inc. | $103 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-16 | EMD Serono, Inc. | $65 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-11 | TG Therapeutics, Inc. | $232 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-09 | Biogen, Inc. | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-09-04 | EMD Serono, Inc. | $7,935 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-04 | EMD Serono, Inc. | $3,795 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-03 | Genentech USA, Inc. | $8 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-09-02 | Novartis Pharmaceuticals Corporation | $59 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-09-02 | EMD Serono, Inc. | $48 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-02 | EMD Serono, Inc. | $33 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-02 | EMD Serono, Inc. | $29 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-02 | EMD Serono, Inc. | $26 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-08-27 | ABBVIE INC. | $117 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-08-26 | Amgen Inc. | $29 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-08-25 | EMD Serono, Inc. | $241 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-25 | Amgen Inc. | $5 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-08-19 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-19 | Amgen Inc. | $25 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-08-15 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-08-14 | EMD Serono, Inc. | $5,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-13 | EMD Serono, Inc. | $956 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-13 | EMD Serono, Inc. | $376 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-13 | EMD Serono, Inc. | $274 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-13 | EMD Serono, Inc. | $176 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-13 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-08-12 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-08-12 | ARGENX US, INC. | $17 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-08-11 | Biogen, Inc. | $343 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, Neurology | 2025 | |
| 2025-08-07 | Xeris Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | KEVEYIS Drug, Carbonic anhydrase inhibitor | 2025 | |
| 2025-08-05 | Eisai Inc. | $19 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-08-04 | Biogen, Inc. | $685 | Consulting Fee | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-08-04 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-07-31 | ARGENX US, INC. | $89 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-07-31 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-28 | UCB, Inc. | $43 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-07-24 | Biogen, Inc. | $15 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-07-23 | TG Therapeutics, Inc. | $4,387 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-07-23 | E.R. Squibb & Sons, L.L.C. | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-07-23 | EMD Serono, Inc. | $226 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-23 | E.R. Squibb & Sons, L.L.C. | $183 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-07-23 | TG Therapeutics, Inc. | $179 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-07-23 | TG Therapeutics, Inc. | $65 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-07-23 | EMD Serono, Inc. | $11 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-22 | EMD Serono, Inc. | $211 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-22 | EMD Serono, Inc. | $122 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-22 | EMD Serono, Inc. | $65 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-17 | Alexion Pharmaceuticals, Inc. | $2,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-07-16 | UCB, Inc. | $35 | Food and Beverage | In-kind items and services | Nayzilam Drug, Neurology | 2025 | |
| 2025-07-16 | Biogen, Inc. | $19 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-07-16 | Biogen, Inc. | $2 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-07-15 | GENZYME CORPORATION | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-14 | E.R. Squibb & Sons, L.L.C. | $175 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-07-14 | Biogen, Inc. | $104 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-07-10 | Biogen, Inc. | $2,055 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYSABRI Biological, Neurology | 2025 | |
| 2025-07-10 | E.R. Squibb & Sons, L.L.C. | $324 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-07-10 | E.R. Squibb & Sons, L.L.C. | $122 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-07-10 | SK Life Science, Inc. | $34 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-10 | E.R. Squibb & Sons, L.L.C. | $10 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-07-09 | EMD Serono, Inc. | $5,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-09 | Alexion Pharmaceuticals, Inc. | $1,327 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-07-09 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2025 | |
| 2025-07-08 | EMD Serono, Inc. | $26 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-01 | E.R. Squibb & Sons, L.L.C. | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-06-28 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-06-27 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-23 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-18 | E.R. Squibb & Sons, L.L.C. | $124 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-06-17 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-06-17 | Alexion Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-06-17 | GENZYME CORPORATION | $6 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-16 | EMD Serono, Inc. | $225 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-16 | EMD Serono, Inc. | $125 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-16 | EMD Serono, Inc. | $65 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-13 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 |
The latest 200 records of 2,277.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-22 | Novartis Pharmaceuticals Corporation | AQUALANE CLINICAL RESEARCH | $201 | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients wit | 2025 |
| 2025-12-19 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $593 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-12-18 | PFIZER INC. | AQUALANE CLINICAL RESEARCH LLC | $2,925 | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIM | 2025 |
| 2025-11-30 | TG Therapeutics, Inc. | AQUALANE CLINICAL RESEARCH | $8,470 | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | 2025 |
| 2025-11-27 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $727 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-11-27 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $3,334 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-11-21 | E.R. Squibb & Sons, L.L.C. | AQUALANE CLINICAL RESEARCH | $1,106 | A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and | 2025 |
| 2025-11-01 | TG Therapeutics, Inc. | AQUALANE CLINICAL RESEARCH | $200 | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | 2025 |
| 2025-10-28 | Novartis Pharmaceuticals Corporation | AQUALANE CLINICAL RESEARCH | $1,333 | A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrut | 2025 |
| 2025-10-27 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $746 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-10-27 | Novartis Pharmaceuticals Corporation | COLLIER NEUROLOGIC SPECIALISTS | $70,046 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2025 |
| 2025-10-27 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $741 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-10-22 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $240 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-10-20 | GENZYME CORPORATION | AQUALANE CLINICAL RESEARCH LLC | $11,252 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-10-08 | Novartis Pharmaceuticals Corporation | COLLIER NEUROLOGIC SPECIALISTS | $385 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2025 |
| 2025-09-29 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $1,121 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-09-29 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $918 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-09-19 | Janssen Research & Development, LLC | AQUALANE CLINICAL RESEARCH LLC | $1,680 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2025 |
| 2025-09-19 | Janssen Research & Development, LLC | AQUALANE CLINICAL RESEARCH LLC | $51 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2025 |
| 2025-09-03 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $999 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-09-03 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $650 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-08-28 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $267 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-08-28 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $1,397 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-08-28 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $370 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-08-28 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $58 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-08-11 | Janssen Research & Development, LLC | AQUALANE CLINICAL RESEARCH LLC | $3,475 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2025 |
| 2025-08-04 | PFIZER INC. | AQUALANE CLINICAL RESEARCH LLC | $10,343 | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIM | 2025 |
| 2025-07-17 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $1,120 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-02 | GENZYME CORPORATION | COLLIER NEUROLOGIC SPECIALISTS LLC | $4,950 | A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profi | 2025 |
| 2025-06-23 | GENZYME CORPORATION | AQUALANE CLINICAL RESEARCH LLC | $2,471 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-06-18 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $784 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-06-18 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $4,446 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-06-12 | Novartis Pharmaceuticals Corporation | AQUALANE CLINICAL RESEARCH LLC | $10,000 | A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrut | 2025 |
| 2025-06-01 | TG Therapeutics, Inc. | AQUALANE CLINICAL RESEARCH | $2,910 | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | 2025 |
| 2025-05-30 | Janssen Research & Development, LLC | AQUALANE CLINICAL RESEARCH LLC | $14,000 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2025 |
| 2025-05-28 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $4,075 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-05-28 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $746 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-05-23 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $702 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-05-22 | Novartis Pharmaceuticals Corporation | AQUALANE CLINICAL RESEARCH LLC | $15,625 | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab | 2025 |
| 2025-05-15 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $1,680 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-05-01 | Janssen Research & Development, LLC | AQUALANE CLINICAL RESEARCH LLC | $5,120 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2025 |
| 2025-05-01 | TG Therapeutics, Inc. | AQUALANE CLINICAL RESEARCH | $2,160 | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | 2025 |
| 2025-04-28 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $4,075 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-04-28 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $593 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-04-28 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $13,105 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-04-22 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $3,371 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-04-20 | TG Therapeutics, Inc. | AQUALANE CLINICAL RESEARCH | $10,000 | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | 2025 |
| 2025-04-07 | GENZYME CORPORATION | AQUALANE CLINICAL RESEARCH LLC | $1,578 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-04-01 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $244 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-04-01 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $1,906 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-04-01 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $87 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-04-01 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $314 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-03-24 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $11,090 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-03-24 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $861 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-03-24 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $555 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-03-17 | Novartis Pharmaceuticals Corporation | AQUALANE CLINICAL RESEARCH LLC | $4,386 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2025 |
| 2025-03-11 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $926 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-27 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $26,210 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-02-27 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $6,347 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-02-27 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $4,075 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-02-27 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $10,104 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-02-27 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $1,109 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-02-27 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $440 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-02-27 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $2,641 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-02-25 | Novartis Pharmaceuticals Corporation | AQUALANE CLINICAL RESEARCH LLC | $23,355 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2025 |
| 2025-02-19 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $10,000 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-02-19 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $1,100 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-02-19 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $950 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute | 2025 |
| 2025-02-05 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $2,618 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-01-31 | Novartis Pharmaceuticals Corporation | AQUALANE CLINICAL RESEARCH | $176,858 | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab | 2025 |
| 2025-01-29 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $3,448 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-01-29 | Amgen Inc. | AQUALANE CLINICAL RESEARCH LLC | $195,280 | A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Sa | 2025 |
| 2025-01-27 | GENZYME CORPORATION | AQUALANE CLINICAL RESEARCH LLC | $15,150 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-01-27 | GENZYME CORPORATION | AQUALANE CLINICAL RESEARCH LLC | $1,578 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-01-27 | GENZYME CORPORATION | AQUALANE CLINICAL RESEARCH LLC | $2,809 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-01-27 | GENZYME CORPORATION | AQUALANE CLINICAL RESEARCH LLC | $3,739 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-01-09 | Novartis Pharmaceuticals Corporation | COLLIER NEUROLOGIC SPECIALISTS | $138,403 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2025 |
| 2025-01-07 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $3,545 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-01-06 | Janssen Research & Development, LLC | AQUALANE CLINICAL RESEARCH LLC | $16,070 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2025 |
| 2025-01-01 | Novartis Pharmaceuticals Corporation | COLLIER NEUROLOGIC SPECIALISTS | $320,153 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2025 |
| 2024-12-30 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $875 | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MU | 2024 |
| 2024-12-30 | Janssen Research & Development, LLC | AQUALANE CLINICAL RESEARCH LLC | $1,630 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2024 |
| 2024-12-18 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $3,080 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2024 |
| 2024-11-26 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $6,630 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2024 |
| 2024-11-26 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $9,891 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2024 |
| 2024-11-18 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $102 | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MU | 2024 |
| 2024-11-15 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $399 | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MU | 2024 |
| 2024-11-12 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $16,400 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2024 |
| 2024-11-04 | ModernaTX, Inc. | AQUALANE CLINICAL RESEARCH | $9,050 | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MU | 2024 |
| 2024-10-15 | GENZYME CORPORATION | Lone Star Neurology | $26,969 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre | 2024 |
| 2024-10-15 | GENZYME CORPORATION | AQUALANE CLINICAL RESEARCH | $6,000 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre | 2024 |
| 2024-10-09 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $366 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2024 |
| 2024-08-16 | TG Therapeutics, Inc. | AQUALANE CLINICAL RESEARCH | $4,500 | Retrospective Evaluation of Infusion Tolerability: BRIUMVI Real-World Observational Survey (ENAMOR) | 2024 |
| 2024-08-16 | TG Therapeutics, Inc. | AQUALANE CLINICAL RESEARCH | $2,500 | Retrospective Evaluation of Infusion Tolerability: BRIUMVI Real-World Observational Survey (ENAMOR) | 2024 |
| 2024-08-16 | TG Therapeutics, Inc. | AQUALANE CLINICAL RESEARCH | $4,500 | Retrospective Evaluation of Infusion Tolerability: BRIUMVI Real-World Observational Survey (ENAMOR) | 2024 |
| 2024-08-16 | TG Therapeutics, Inc. | AQUALANE CLINICAL RESEARCH | $2,500 | Retrospective Evaluation of Infusion Tolerability: BRIUMVI Real-World Observational Survey (ENAMOR) | 2024 |
| 2024-06-11 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $5,700 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2024 |
| 2024-06-11 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $10,000 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2024 |
| 2024-06-11 | H. Lundbeck A S | AQUALANE CLINICAL RESEARCH LLC | $1,760 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2024 |
| 2024-06-10 | GENZYME CORPORATION | AQUALANE CLINICAL RESEARCH | $4,509 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Naples, FL, county Collier County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) Naples, FL | County Collier County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 19,704 | 398,291 | 22,416,077 |
| Population, 2020 census P1 | 19,115 | 375,752 | 21,538,187 |
| Median age B01002 | 67.3 | 53.3 | 42.6 |
| Under 18 B01001 | 9.0% | 16.3% | 19.5% |
| 65 and over B01001 | 55.8% | 33.8% | 21.3% |
| Households B11001 | 9,836 | 165,875 | 8,752,810 |
| Foreign born B05002 | 12.7% | 24.6% | 21.9% |
| Median household income B19013 | $153,182 | $90,045 | $74,568 |
| Median family income B19113 | $203,791 | $108,010 | $89,891 |
| Per capita income B19301 | $152,378 | $62,079 | $42,609 |
| Poverty rate B17001 | 6.5% | 10.7% | 12.6% |
| Unemployment rate B23025 | 2.3% | 3.9% | 4.8% |
| Civilian labor force B23025 | 6,376 | 174,612 | 11,016,578 |
| Mean commute (minutes) B08013 | 22.4 | 26.1 | 28.0 |
| Bachelor's degree or higher B15003 | 64.3% | 40.3% | 34.1% |
| Housing units B25001 | 18,902 | 239,406 | 10,256,470 |
| Owner-occupied B25003 | 82.1% | 76.6% | 67.6% |
| Renters B25003 | 17.9% | 23.4% | 32.4% |
| Median home value B25077 | $1,525,600 | $540,700 | $359,000 |
| Median gross rent B25064 | $2,305 | $1,862 | $1,669 |
| White, not Hispanic B03002 | 88.9% | 61.4% | 50.4% |
| Black B03002 | 3.3% | 6.4% | 14.6% |
| Hispanic or Latino B03002 | 4.8% | 28.2% | 27.4% |
| Asian B03002 | 0.8% | 1.5% | 2.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Naples, FL.
Comments